C3i at BioPharma Asia Convention 2012

C3i is the leading provider of end-to-end technology services for sponsors and CROs running global clinical trials. C3i’s portfolio of business process outsourcing services for EDC, IVRS/IRT, CTMS, and ePRO applications includes: 24×7 multi-lingual contact center, systems integration, technology training, asset management, provisioning, technical site assessments, and applicaton hosting exclusively tailored for the needs of clinical professionals. C3i works with …

Elcam Medical at BioPharma Asia Convention 2012

Elcam Medical, exhibitor at BioPharma Asia Convention 2012 is a leading worldwide OEM supplier of Drug Delivery, Fluid Management and Vital Signs Monitoring systems and devices. Elcam is an innovative customer-centric, full-service partner with capabilities ranging from design through manufacturing with particular expertise in high volume precision molding and high speed assembly. Production facilities in the EU, US and Israel. …

The power of #RareDisease patients

Siren Interactive kindly provided this guest blog post from their blog, SirenSong. It was written by their Founder and President, Wendy White, who will be speaking at the World Orphan Drug Congress USA in April on the topic, ‘Clinical trial recruitment acceleration through social media'. Thanks to the Pew Internet Foundation, we have a lot of data about ePatients. These …

Exhibitor spotlight: Colder Products Company

Colder Products Company is the leading provider of quick disconnect couplings, fittings and connectors for life sciences, industrial and chemical handling markets. Used in a broad range of applications, innovative coupling and connection technologies from Colder allow flexible tubing to be quickly and safely connected and disconnected. Colder Products will be exhibiting at booth C3 at BioPharma Asia Convention 2012 …

What does disappointing results of Gilead’s oral Hep C drug mean for early development in direct-acting antivirals?

GS-7977 was the major asset behind Gilead's $10.8billion acquisition of Pharmasset last year and was at the forefront of big pharma's bet in this field. The megablockbuster prospect of a next-gen oral therapy to quell the hep C virus without the use of interferons (which have well-described side-effects – fatigue, influzena-like symptoms, hematologic abnormalities and neuropsychiatric symptoms) is something that …

4 Reasons why the pharma industry is facing exponential change

The global pharmaceutical industry is experiencing exponential change. A mass of conflicting drivers are competing to make the prediction of value ever more complex. 1) Demographics – Demographics are pushing market potential upwards through an ageing population and the move to lifestyle related diseases in the increasingly affluent developing markets of the world. 2) Economic climate – The counter pressures …